This doctoral training programme aims to create a new generation of researchers, capable of integrating quantitative and analytical methods to drive discovery and innovation in the biomedical, biotechnology and pharmaceutical sectors. The programme includes a one-year MSc in Interdisciplinary Biomedical Research and a three-year PhD supervised by internationally leading experts from the physical and biomedical sciences and industry.
Project title: Peptidomimetic Inhibitors for the MraY-protein E interaction site as anti-Pseudomonas therapeutics
Warwick supervisor: Professor Timothy Bugg
Industry supervisor: Dr Andrew Merritt (LifeArc)
Project summary: Peptido-mimetic inhibitors of the MraY-protein E interaction as anti-Pseudomonas therapeutics Many antibiotics target cell wall peptidoglycan biosynthesis in bacteria. However the spread of anti-microbial resistance requires the development of new antibiotics. Translocase 1 (MraY) catalyses the first step in cell wall biosynthesis and interacts with protein E from bacteriophage phiX174. We have found that peptides of general sequence Arg-Trp-x-x-Trp, which block interaction of MraY and protein E, show antimicrobial activity against antibiotic resistant strains of Pseudomonas and other gram-negative pathogens. In this project the student will involve chemical synthesis of new peptido-mimetic analogues, guided by docking studies at LifeArc Ltd, to generate a new class of antibiotics.
Applicants should have experience in chemical synthesis and interests in medicinal chemistry.
Project title: Modelling Receptor Uptake in Glucose Homeostasis
Warwick supervisor: Professor Michael Chappell
Industry supervisor: Dr Robert Willis (Sosei Heptares)
Project summary: The failure to regulate glucose levels in humans can lead to a range of diseases, most notably diabetes. This PhD project will utilise preclinical and clinical data from Sosei Heptares, to develop mathematical models that describe the interaction of novel pharmaceutical agents with their cellular receptor(s) and predict their subsequent action on the pathways that regulate glucose homeostasis. Development of these models will provide a tool that can be used to interrogate how the various pathways interact, to select applicable patient populations and disease indicators and to help design clinical trials that enable the development of novel strategies for disease intervention.
Applicants should have a good undergraduate degree in mathematics, engineering, statistics or a related discipline.